2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants
A Report of the American College of Cardiology Solution Set Oversight Committee
Gordon F. Tomaselli, Kenneth W. Mahaffey, Adam Cuker, Paul P. Dobesh, John U. Doherty, John W. Eikelboom, Roberta Florido, Ty J. Gluckman, William J. Hucker, Roxana Mehran, Steven R. Messé, Alexander C. Perino, Fatima Rodriguez, Ravindra Sarode, Deborah M. Siegal and Barbara S. Wiggins
Assessing Bleed Severity and Managing Major and Non-Major Bleeds
DOAC = direct-acting oral anticoagulant; IV = intravenous; OAC = oral anticoagulant, including DOACs and VKAs; PCC = prothrombin complex concentrate; PO = per os “by mouth”; RBCs = red blood cells; VKA = vitamin K antagonist
∗Reversal/hemostatic agents include repletion strategies such as PCCs, plasma, vitamin K, and specific reversal agents for DOACs (e.g., idarucizumab for dabigatran; andexanet alfa for apixaban or rivaroxaban).